Fig. 3From: Bispecific T cell engagers: an emerging therapy for management of hematologic malignanciesTargets of bispecific B cell-recruiting antibodies. CD19 and CD20 are targets for treatment of NHL; CD19 is the target for treatment of acute lymphocytic leukemia; CD123, CD33, CLEC12A, WT1, and FLT3 are targets for treatment of acute myeloid leukemia; BCMA, CD38, and GPRC5D are targets for treatment of multiple myelomaBack to article page